Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with PharmaCell B.V and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL; and the University of Texas M.D. Anderson Cancer Center for multi-arm clinical trials for TIL therapy. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone650-260-7120
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions
What is Iovance Biotherapeutics' stock symbol?
Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."
How were Iovance Biotherapeutics' earnings last quarter?
Iovance Biotherapeutics Inc (NASDAQ:IOVA) posted its earnings results on Monday, August, 6th. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.02. View Iovance Biotherapeutics' Earnings History.
When is Iovance Biotherapeutics' next earnings date?
What price target have analysts set for IOVA?
7 brokerages have issued 12-month price objectives for Iovance Biotherapeutics' shares. Their predictions range from $20.00 to $29.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $24.8333 in the next twelve months. This suggests a possible upside of 160.0% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics.
What is the consensus analysts' recommendation for Iovance Biotherapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics.
What are Wall Street analysts saying about Iovance Biotherapeutics stock?
Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
- 1. Chardan Capital analysts commented, "We expect more visibility as Iovance plans to engage with the FDA in 2019 to define a regulatory path for LN-145 in 2nd-line cervical cancer, for which it recently received Fast Track Designation. We expect Iovance will be able to advance this program relatively quickly based on learnings from lifileucel. We expect to hear more on manufacturing and preclinical programs in 2019, as the company’s focus expands beyond the current phase II trials. Iovance is in the late stages of site selection for a manufacturing facility and expects to provide updates in 2Q19. To us, establishing an internal manufacturing facility will be a key step in commercial execution. Iovance is also planning to file an IND for peripheral blood lymphocytes (PBL) in hematological malignancies in 2019. We understand this program uses a distinct and shorter manufacturing process." (2/28/2019)
- 2. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (1/15/2019)
- 3. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating and price target of $26. Our target is based on our clinical net present value (NPV) model, which derives its primary value from LN-144 for metastatic melanoma currently. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (11/12/2018)
Has Iovance Biotherapeutics been receiving favorable news coverage?
Media coverage about IOVA stock has trended somewhat negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Iovance Biotherapeutics earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Iovance Biotherapeutics' key competitors?
Some companies that are related to Iovance Biotherapeutics include Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD) and Orchard Therapeutics (ORTX).
What other stocks do shareholders of Iovance Biotherapeutics own?
Who are Iovance Biotherapeutics' key executives?
Iovance Biotherapeutics' management team includes the folowing people:
- Dr. Maria Fardis, CEO, Pres & Director (Age 51)
- Mr. Timothy E. Morris, CFO, Principal Accounting Officer & Corp. Sec. (Age 57)
- Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)
- Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)
- Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62)
Who are Iovance Biotherapeutics' major shareholders?
Iovance Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (9.94%), venBio Select Advisor LLC (8.33%), BlackRock Inc. (7.13%), Broadfin Capital LLC (4.83%), Great Point Partners LLC (4.52%) and Victory Capital Management Inc. (2.45%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Institutional Ownership Trends for Iovance Biotherapeutics.
Which institutional investors are selling Iovance Biotherapeutics stock?
IOVA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artal Group S.A., Nantahala Capital Management LLC, Rhenman & Partners Asset Management AB, Squarepoint Ops LLC, Cheyne Capital Management UK LLP, MetLife Investment Advisors LLC and New York State Common Retirement Fund. View Insider Buying and Selling for Iovance Biotherapeutics.
Which institutional investors are buying Iovance Biotherapeutics stock?
IOVA stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, BlackRock Inc., Great Point Partners LLC, RA Capital Management LLC, venBio Select Advisor LLC, Bank of America Corp DE, Broadfin Capital LLC and Victory Capital Management Inc.. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Insider Buying and Selling for Iovance Biotherapeutics.
How do I buy shares of Iovance Biotherapeutics?
Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iovance Biotherapeutics' stock price today?
One share of IOVA stock can currently be purchased for approximately $9.55.
How big of a company is Iovance Biotherapeutics?
Iovance Biotherapeutics has a market capitalization of $1.18 billion. The biotechnology company earns $-123,580,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.
What is Iovance Biotherapeutics' official website?
How can I contact Iovance Biotherapeutics?
Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]
MarketBeat Community Rating for Iovance Biotherapeutics (NASDAQ IOVA)
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
